Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial
Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection. We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested posi...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2023-01, Vol.76 (2), p.185-191 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 191 |
|---|---|
| container_issue | 2 |
| container_start_page | 185 |
| container_title | Clinical infectious diseases |
| container_volume | 76 |
| creator | Ben Abdallah, Saoussen Mhalla, Yosra Trabelsi, Imen Sekma, Adel Youssef, Rim Bel Haj Ali, Khaoula Ben Soltane, Houda Yacoubi, Hajer Msolli, Mohamed Amine Stambouli, Nejla Beltaief, Kaouthar Grissa, Mohamed Habib Khrouf, Meriem Mezgar, Zied Loussaief, Chawki Bouida, Wahid Razgallah, Rabie Hezbri, Karima Belguith, Asma Belkacem, Naouel Dridi, Zohra Boubaker, Hamdi Boukef, Riadh Nouira, Semir |
| description | Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection.
We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested positive for COVID-19 without end-organ failure were randomized to oral zinc (n = 231) or matching placebo (n = 239) for 15 days. The primary combined outcome was death due to COVID-19 or intensive care unit (ICU) admission ≤30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19-related hospitalization for outpatients.
190 patients (40.4%) were ambulatory and 280 patients (59.6%) were hospitalized. Mortality at 30 days was 6.5% in the zinc group and 9.2% in the placebo group (OR: .68; 95% CI .34-1.35); ICU admission rates were, respectively, 5.2% and 11.3% (OR: .43; 95% CI .21-.87). Combined outcome was lower in the zinc group versus the placebo group (OR: .58; 95% CI .33-.99). Consistent results were observed in prespecified subgroups of patients aged |
| doi_str_mv | 10.1093/cid/ciac807 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2735864788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2735864788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-c281b55cc9f8257144981ee78749db84f4bc867078cd8bd2ab73f9f13ec6ae303</originalsourceid><addsrcrecordid>eNo9kN9LwzAQx4Mobk6ffJc8ClJNmqZJfZubv2AwkYngS0nTK4ukzUxaZeIfb8emD8d9OT53HB-ETim5pCRjV9qUfSktidhDQ8qZiFKe0f0-Ey6jRDI5QEchvBNCqST8EA1YylJBk2SIfhZfRkM0Vcau8dwri99Mo7FpcLsEvPCg2hqaFrsKP6nW9DHgV9Mu8cR516hP47uApyaACoBjQrNrPMbPqildbb6hxFPXFRaiG2uast9pWu-s7ecLb5Q9RgeVsgFOdn2EXu5uF5OHaDa_f5yMZ5FmcdpGOpa04FzrrJIx3_ydSQogpEiyspBJlRRapoIIqUtZlLEqBKuyijLQqQJG2Aidb--uvPvoILR5bYIGa1UDrgt5LBiXaSKk7NGLLaq9C8FDla-8qZVf55TkG915rzvf6e7ps93hrqih_Gf__LJfq-p8Fg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2735864788</pqid></control><display><type>article</type><title>Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ben Abdallah, Saoussen ; Mhalla, Yosra ; Trabelsi, Imen ; Sekma, Adel ; Youssef, Rim ; Bel Haj Ali, Khaoula ; Ben Soltane, Houda ; Yacoubi, Hajer ; Msolli, Mohamed Amine ; Stambouli, Nejla ; Beltaief, Kaouthar ; Grissa, Mohamed Habib ; Khrouf, Meriem ; Mezgar, Zied ; Loussaief, Chawki ; Bouida, Wahid ; Razgallah, Rabie ; Hezbri, Karima ; Belguith, Asma ; Belkacem, Naouel ; Dridi, Zohra ; Boubaker, Hamdi ; Boukef, Riadh ; Nouira, Semir</creator><creatorcontrib>Ben Abdallah, Saoussen ; Mhalla, Yosra ; Trabelsi, Imen ; Sekma, Adel ; Youssef, Rim ; Bel Haj Ali, Khaoula ; Ben Soltane, Houda ; Yacoubi, Hajer ; Msolli, Mohamed Amine ; Stambouli, Nejla ; Beltaief, Kaouthar ; Grissa, Mohamed Habib ; Khrouf, Meriem ; Mezgar, Zied ; Loussaief, Chawki ; Bouida, Wahid ; Razgallah, Rabie ; Hezbri, Karima ; Belguith, Asma ; Belkacem, Naouel ; Dridi, Zohra ; Boubaker, Hamdi ; Boukef, Riadh ; Nouira, Semir</creatorcontrib><description>Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection.
We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested positive for COVID-19 without end-organ failure were randomized to oral zinc (n = 231) or matching placebo (n = 239) for 15 days. The primary combined outcome was death due to COVID-19 or intensive care unit (ICU) admission ≤30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19-related hospitalization for outpatients.
190 patients (40.4%) were ambulatory and 280 patients (59.6%) were hospitalized. Mortality at 30 days was 6.5% in the zinc group and 9.2% in the placebo group (OR: .68; 95% CI .34-1.35); ICU admission rates were, respectively, 5.2% and 11.3% (OR: .43; 95% CI .21-.87). Combined outcome was lower in the zinc group versus the placebo group (OR: .58; 95% CI .33-.99). Consistent results were observed in prespecified subgroups of patients aged <65 years, those with comorbidity, and those who needed oxygen therapy at baseline. Length of hospital stay was shorter in the zinc group versus the placebo group (difference: 3.5 days; 95% CI 2.76-4.23) in the inpatient group; duration of COVID-19 symptoms decreased with zinc treatment versus placebo in outpatients (difference: 1.9 days; 95% CI .62-2.6). No severe adverse events were observed during the study.
Our results showed that, in COVID-19 patients, oral zinc can decrease 30-day death, ICU admission rate and can shorten symptom duration. Clinical Trials Registration. ClinicalTrials.gov, NCT05212480.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciac807</identifier><identifier>PMID: 36367144</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; COVID-19 ; Double-Blind Method ; Humans ; Prospective Studies ; SARS-CoV-2 ; Treatment Outcome ; Zinc - therapeutic use</subject><ispartof>Clinical infectious diseases, 2023-01, Vol.76 (2), p.185-191</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-c281b55cc9f8257144981ee78749db84f4bc867078cd8bd2ab73f9f13ec6ae303</citedby><cites>FETCH-LOGICAL-c326t-c281b55cc9f8257144981ee78749db84f4bc867078cd8bd2ab73f9f13ec6ae303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36367144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ben Abdallah, Saoussen</creatorcontrib><creatorcontrib>Mhalla, Yosra</creatorcontrib><creatorcontrib>Trabelsi, Imen</creatorcontrib><creatorcontrib>Sekma, Adel</creatorcontrib><creatorcontrib>Youssef, Rim</creatorcontrib><creatorcontrib>Bel Haj Ali, Khaoula</creatorcontrib><creatorcontrib>Ben Soltane, Houda</creatorcontrib><creatorcontrib>Yacoubi, Hajer</creatorcontrib><creatorcontrib>Msolli, Mohamed Amine</creatorcontrib><creatorcontrib>Stambouli, Nejla</creatorcontrib><creatorcontrib>Beltaief, Kaouthar</creatorcontrib><creatorcontrib>Grissa, Mohamed Habib</creatorcontrib><creatorcontrib>Khrouf, Meriem</creatorcontrib><creatorcontrib>Mezgar, Zied</creatorcontrib><creatorcontrib>Loussaief, Chawki</creatorcontrib><creatorcontrib>Bouida, Wahid</creatorcontrib><creatorcontrib>Razgallah, Rabie</creatorcontrib><creatorcontrib>Hezbri, Karima</creatorcontrib><creatorcontrib>Belguith, Asma</creatorcontrib><creatorcontrib>Belkacem, Naouel</creatorcontrib><creatorcontrib>Dridi, Zohra</creatorcontrib><creatorcontrib>Boubaker, Hamdi</creatorcontrib><creatorcontrib>Boukef, Riadh</creatorcontrib><creatorcontrib>Nouira, Semir</creatorcontrib><title>Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection.
We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested positive for COVID-19 without end-organ failure were randomized to oral zinc (n = 231) or matching placebo (n = 239) for 15 days. The primary combined outcome was death due to COVID-19 or intensive care unit (ICU) admission ≤30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19-related hospitalization for outpatients.
190 patients (40.4%) were ambulatory and 280 patients (59.6%) were hospitalized. Mortality at 30 days was 6.5% in the zinc group and 9.2% in the placebo group (OR: .68; 95% CI .34-1.35); ICU admission rates were, respectively, 5.2% and 11.3% (OR: .43; 95% CI .21-.87). Combined outcome was lower in the zinc group versus the placebo group (OR: .58; 95% CI .33-.99). Consistent results were observed in prespecified subgroups of patients aged <65 years, those with comorbidity, and those who needed oxygen therapy at baseline. Length of hospital stay was shorter in the zinc group versus the placebo group (difference: 3.5 days; 95% CI 2.76-4.23) in the inpatient group; duration of COVID-19 symptoms decreased with zinc treatment versus placebo in outpatients (difference: 1.9 days; 95% CI .62-2.6). No severe adverse events were observed during the study.
Our results showed that, in COVID-19 patients, oral zinc can decrease 30-day death, ICU admission rate and can shorten symptom duration. Clinical Trials Registration. ClinicalTrials.gov, NCT05212480.</description><subject>Adult</subject><subject>COVID-19</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Treatment Outcome</subject><subject>Zinc - therapeutic use</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kN9LwzAQx4Mobk6ffJc8ClJNmqZJfZubv2AwkYngS0nTK4ukzUxaZeIfb8emD8d9OT53HB-ETim5pCRjV9qUfSktidhDQ8qZiFKe0f0-Ey6jRDI5QEchvBNCqST8EA1YylJBk2SIfhZfRkM0Vcau8dwri99Mo7FpcLsEvPCg2hqaFrsKP6nW9DHgV9Mu8cR516hP47uApyaACoBjQrNrPMbPqildbb6hxFPXFRaiG2uast9pWu-s7ecLb5Q9RgeVsgFOdn2EXu5uF5OHaDa_f5yMZ5FmcdpGOpa04FzrrJIx3_ydSQogpEiyspBJlRRapoIIqUtZlLEqBKuyijLQqQJG2Aidb--uvPvoILR5bYIGa1UDrgt5LBiXaSKk7NGLLaq9C8FDla-8qZVf55TkG915rzvf6e7ps93hrqih_Gf__LJfq-p8Fg</recordid><startdate>20230113</startdate><enddate>20230113</enddate><creator>Ben Abdallah, Saoussen</creator><creator>Mhalla, Yosra</creator><creator>Trabelsi, Imen</creator><creator>Sekma, Adel</creator><creator>Youssef, Rim</creator><creator>Bel Haj Ali, Khaoula</creator><creator>Ben Soltane, Houda</creator><creator>Yacoubi, Hajer</creator><creator>Msolli, Mohamed Amine</creator><creator>Stambouli, Nejla</creator><creator>Beltaief, Kaouthar</creator><creator>Grissa, Mohamed Habib</creator><creator>Khrouf, Meriem</creator><creator>Mezgar, Zied</creator><creator>Loussaief, Chawki</creator><creator>Bouida, Wahid</creator><creator>Razgallah, Rabie</creator><creator>Hezbri, Karima</creator><creator>Belguith, Asma</creator><creator>Belkacem, Naouel</creator><creator>Dridi, Zohra</creator><creator>Boubaker, Hamdi</creator><creator>Boukef, Riadh</creator><creator>Nouira, Semir</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230113</creationdate><title>Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial</title><author>Ben Abdallah, Saoussen ; Mhalla, Yosra ; Trabelsi, Imen ; Sekma, Adel ; Youssef, Rim ; Bel Haj Ali, Khaoula ; Ben Soltane, Houda ; Yacoubi, Hajer ; Msolli, Mohamed Amine ; Stambouli, Nejla ; Beltaief, Kaouthar ; Grissa, Mohamed Habib ; Khrouf, Meriem ; Mezgar, Zied ; Loussaief, Chawki ; Bouida, Wahid ; Razgallah, Rabie ; Hezbri, Karima ; Belguith, Asma ; Belkacem, Naouel ; Dridi, Zohra ; Boubaker, Hamdi ; Boukef, Riadh ; Nouira, Semir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-c281b55cc9f8257144981ee78749db84f4bc867078cd8bd2ab73f9f13ec6ae303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>COVID-19</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Treatment Outcome</topic><topic>Zinc - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ben Abdallah, Saoussen</creatorcontrib><creatorcontrib>Mhalla, Yosra</creatorcontrib><creatorcontrib>Trabelsi, Imen</creatorcontrib><creatorcontrib>Sekma, Adel</creatorcontrib><creatorcontrib>Youssef, Rim</creatorcontrib><creatorcontrib>Bel Haj Ali, Khaoula</creatorcontrib><creatorcontrib>Ben Soltane, Houda</creatorcontrib><creatorcontrib>Yacoubi, Hajer</creatorcontrib><creatorcontrib>Msolli, Mohamed Amine</creatorcontrib><creatorcontrib>Stambouli, Nejla</creatorcontrib><creatorcontrib>Beltaief, Kaouthar</creatorcontrib><creatorcontrib>Grissa, Mohamed Habib</creatorcontrib><creatorcontrib>Khrouf, Meriem</creatorcontrib><creatorcontrib>Mezgar, Zied</creatorcontrib><creatorcontrib>Loussaief, Chawki</creatorcontrib><creatorcontrib>Bouida, Wahid</creatorcontrib><creatorcontrib>Razgallah, Rabie</creatorcontrib><creatorcontrib>Hezbri, Karima</creatorcontrib><creatorcontrib>Belguith, Asma</creatorcontrib><creatorcontrib>Belkacem, Naouel</creatorcontrib><creatorcontrib>Dridi, Zohra</creatorcontrib><creatorcontrib>Boubaker, Hamdi</creatorcontrib><creatorcontrib>Boukef, Riadh</creatorcontrib><creatorcontrib>Nouira, Semir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ben Abdallah, Saoussen</au><au>Mhalla, Yosra</au><au>Trabelsi, Imen</au><au>Sekma, Adel</au><au>Youssef, Rim</au><au>Bel Haj Ali, Khaoula</au><au>Ben Soltane, Houda</au><au>Yacoubi, Hajer</au><au>Msolli, Mohamed Amine</au><au>Stambouli, Nejla</au><au>Beltaief, Kaouthar</au><au>Grissa, Mohamed Habib</au><au>Khrouf, Meriem</au><au>Mezgar, Zied</au><au>Loussaief, Chawki</au><au>Bouida, Wahid</au><au>Razgallah, Rabie</au><au>Hezbri, Karima</au><au>Belguith, Asma</au><au>Belkacem, Naouel</au><au>Dridi, Zohra</au><au>Boubaker, Hamdi</au><au>Boukef, Riadh</au><au>Nouira, Semir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2023-01-13</date><risdate>2023</risdate><volume>76</volume><issue>2</issue><spage>185</spage><epage>191</epage><pages>185-191</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection.
We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested positive for COVID-19 without end-organ failure were randomized to oral zinc (n = 231) or matching placebo (n = 239) for 15 days. The primary combined outcome was death due to COVID-19 or intensive care unit (ICU) admission ≤30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19-related hospitalization for outpatients.
190 patients (40.4%) were ambulatory and 280 patients (59.6%) were hospitalized. Mortality at 30 days was 6.5% in the zinc group and 9.2% in the placebo group (OR: .68; 95% CI .34-1.35); ICU admission rates were, respectively, 5.2% and 11.3% (OR: .43; 95% CI .21-.87). Combined outcome was lower in the zinc group versus the placebo group (OR: .58; 95% CI .33-.99). Consistent results were observed in prespecified subgroups of patients aged <65 years, those with comorbidity, and those who needed oxygen therapy at baseline. Length of hospital stay was shorter in the zinc group versus the placebo group (difference: 3.5 days; 95% CI 2.76-4.23) in the inpatient group; duration of COVID-19 symptoms decreased with zinc treatment versus placebo in outpatients (difference: 1.9 days; 95% CI .62-2.6). No severe adverse events were observed during the study.
Our results showed that, in COVID-19 patients, oral zinc can decrease 30-day death, ICU admission rate and can shorten symptom duration. Clinical Trials Registration. ClinicalTrials.gov, NCT05212480.</abstract><cop>United States</cop><pmid>36367144</pmid><doi>10.1093/cid/ciac807</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2023-01, Vol.76 (2), p.185-191 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2735864788 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult COVID-19 Double-Blind Method Humans Prospective Studies SARS-CoV-2 Treatment Outcome Zinc - therapeutic use |
| title | Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Twice-Daily%20Oral%20Zinc%20in%20the%20Treatment%20of%20Patients%20With%20Coronavirus%20Disease%202019:%20A%20Randomized%20Double-Blind%20Controlled%20Trial&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Ben%20Abdallah,%20Saoussen&rft.date=2023-01-13&rft.volume=76&rft.issue=2&rft.spage=185&rft.epage=191&rft.pages=185-191&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciac807&rft_dat=%3Cproquest_cross%3E2735864788%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2735864788&rft_id=info:pmid/36367144&rfr_iscdi=true |